Evidence Hub

BS33 The interplay of calcium fluxes and calcium buffering in heart failure and treatment with PDE5 inhibition

Mohammed Obeidat

2025

10 participants

Abstract

Introduction Heart failure (HF) is marked by impaired calcium (Ca2+) handling, which compromises contractility and heightens arrhythmogenic risk. Ca2+ buffering within cardiac myocytes is essential for stabilizing intracellular Ca2+. It is underexplored in HF, especially in large-animal models. This study examines how HF alters Ca2+ buffering power and investigates the potential of phosphodiesterase inhibition in restoring Ca2+ dynamics. Methods HF was induced in adult sheep through tachypacing, and animals were divided into three groups: control, HF (n=10), and HF treated with tadalafil (20 mg daily, n=6). Ventricular cardiac myocytes were isolated, and intracellular Ca2+ was measured using Fluo-5F. Voltage clamp was achieved via a perforated patch clamp. Sarcoplasmic reticulum (SR) Ca2+ content and cellular buffering properties were measured by applying a 5 mM caffeine and 20 mM 2,3-butanedione monoxime solution. Protein levels were quantified using western blotting. All data were analysed with nested statistical models. Results HF significantly reduced Ca2+ transient amplitude compared to controls (325.2±34.6nmol/L vs. 169.0±16.8nmol/L, p=0.005), with tadalafil treatment showing no notable improvement (149.4±30.5nmol/L, p=0.96 vs. HF). Ca2+ influx via the L-type Ca2+ channel was also reduced in HF (peak current density 1.26±0.17pA/pF vs. 2.10±0.16pA/pF in controls, p=0.007), this remained impaired in the tadalafil group (1.32±0.22pA/pF, p=0.99 vs. HF). SR Ca2+ content…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free